<DOC>
	<DOCNO>NCT00440271</DOCNO>
	<brief_summary>The primary purpose study : 1 . Demonstrate safety efficacy tipranavir/ritonavir ( TPV/r ) among racially diverse HIV+ population ( male female ) three-class ( nucleoside reverse transcriptase inhibitor ( NRTI ) , non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , protease inhibitor ( PI ) ) experience document resistance one PI . 2 . Determine pharmacokinetic data racially gender diverse population . 3 . Determine potential utility use therapeutic drug monitoring ( TDM ) improve efficacy outcome .</brief_summary>
	<brief_title>SPRING : Safety , Efficacy , Pharmacokinetics tipRanavir/r IN Race/Gender HIV+ Patients Randomized TDM SoC</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Main inclusion criterion study : 1 . HIV1 infect adult , men woman least 18 year age . 2 . 3class ( nucleoside reverse transcriptase inhibitor ( NRTI ) , nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , protease inhibitor ( PI ) ) treatmentexperienced ( min 3months duration class ) resistance one PI ( screen resistance test ) . NNRTInaïve patient genotypically document NNRTIresistance mutation past screen resistance test would eligible . 3 . CD4+ T lymphocyte count &gt; =50 cells/mm3 . 4 . HIV1 viral load &gt; =1,000 copies/mL screening . 5 . The antiretroviral ( ARV ) study treatment regimen must consist TPV/r combo optimize background regimen ( OBR ) 24 agent : N ( ) RTIs ( NRTI NtRTI ) , enfuvirtide ( ENF ) , and/or , available , trial approve expanded access program ( EAP ) investigational agent . 6 . Acceptable screen laboratory value indicate adequate baseline organ function . 7 . Acceptable medical history chest Xray without evidence active disease electrocardiogram ( ECG ) without clinically important abnormality within one year study . 8 . A reliable method barrier contraception use female patient childbearing potential . Main exclusion criterion study : 1 . Known hypersensitivity tipranavir ( TPV ) ritonavir ( RTV ) . 2 . ARV medication naïve . 3 . Genotypic resistance TPV ( define TPV mutation score &gt; 7 ) . 4 . Patients recent drug holiday , define antiretroviral ( ARV ) medication least 7 consecutive day within month prior screen . 5 . Prior tipranavir use . 6 . Inability adhere requirement protocol . 7 . Patients prior history hemorrhagic stroke intracranial aneurysm . 8 . Patients history ischemic stroke , neurosurgery skull trauma within 4 week prior screen . 9 . History Progressive Multifocal Leukoencephalopathy , Visceral Kaposi 's Sarcoma , and/or malignancy . 10 . Any acquired immunodeficiency syndrome ( AIDS ) define illness unresolved , symptomatic stable treatment least 12 week screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>